4142:TPE
Adimmune Corp
NT$१६.३५
arrow_downward
-१.५१%(-०.२५) १ दि
६ नोव्हें, १:३०:०४ PM [GMT]+८ · TWD
search
सर्व सिम्बॉल
| सिम्बॉल | किंमत | बदल | % बदल |
|---|
insights_auto4142 साठी टॉप इनसाइट जनरेट करत आहे...
उघडा
NT$१६.०५
उच्च
NT$१६.५०
कमी
NT$१५.६५
मार्केट कॅप
७.०२ अब्ज
सरासरी उलाढाल
१०.७६ लाख
उलाढाल
२१.५९ लाख
५२ आठवड्यांतील उच्चांक
NT$२२.५०
५२ आठवड्यांतील नीचांक
NT$१५.६५
EPS
-NT$०.३४
थकित शेअर
२३.५३ कोटी
कर्मचाऱ्यांची संख्या
५६४
उघडा
NT$१६.०५
उच्च
NT$१६.५०
कमी
NT$१५.६५
मार्केट कॅप
७.०२ अब्ज
सरासरी उलाढाल
१०.७६ लाख
उलाढाल
२१.५९ लाख
५२ आठवड्यांतील उच्चांक
NT$२२.५०
५२ आठवड्यांतील नीचांक
NT$१५.६५
EPS
-NT$०.३४
थकित शेअर
२३.५३ कोटी
कर्मचाऱ्यांची संख्या
५६४
बातम्यांच्या स्टोरी
वेब स्रोत आणि बातमी भागीदारांकडून
Finviz
·
६ मिनिटांपूर्वी
PSQ Holdings Shrinks Losses And Cash Burn, But Slowing Growth, A Steep Q4 Target And NYSE Listing Risk Define The Setup
Reuters Connect
·
१ तासापूर्वी
Traders work on the floor of the NYSE in New York
kalkine.ca
·
२२ मिनिटांपूर्वी
Can Small Caps Valued at USD 271.24 Million to USD 709.02 Million Back Up Their Records, Led by ACNB Corporation (NASDAQ:ACNB), California BanCorp (NASDAQ:BCAL), Avidbank Holdings (NASDAQ:AVBH), Acme United (NYSEAMERICAN:ACU) an
Barchart.com
·
४५ मिनिटांपूर्वी
Nasdaq Rout Gives Way to Unusual Options Activity and Bullish Bets on Nvidia, AT&T and Alphabet Stocks
प्रोफाइल
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp बद्दल